Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy,Journal of Cachexia, Sarcopenia and Muscle

当前位置： X-MOL 学术 › J. Cachexia Sarcopenia Muscle › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy
Journal of Cachexia, Sarcopenia and Muscle ( IF 9.4 ) Pub Date : 2021-08-23 , DOI: 10.1002/jcsm.12758
Pauline Morigny _{1,

2,

3} , Doris Kaltenecker _{1,

2,

3} , Julia Zuber _{1,

2,

3} , Juliano Machado _{1,

2,

3} , Lisa Mehr _{1,

2,

3} , Foivos-Filippos Tsokanos _{1,

2,

3} , Hanna Kuzi _{4,

5} , Chris D Hermann ₅ , Michael Voelkl ₆ , German Monogarov ₇ , Christoph Springfeld ₈ , Victor Laurent _{1,

2,

3} , Bernd Engelmann ₆ , Helmut Friess ₄ , Inka Zörnig ₈ , Achim Krüger ₅ , Jeroen Krijgsveld _{7,

9} , Olga Prokopchuk _{4,

5} , Søren Fisker Schmidt _{1,

2,

3} , Maria Rohm _{1,

2,

3} , Stephan Herzig _{1,

2,

3,

10} , Mauricio Berriel Diaz _{1,

2,

3}

Affiliation

Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany.
Department of Surgery, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
School of Medicine, Institutes of Molecular Immunology and Experimental Oncology, Technical University of Munich, Munich, Germany.
Institute of Laboratory Medicine, University Hospital Ludwig-Maximilian University, Munich, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Medical Oncology, National Center for Tumor Diseases and Internal Medicine VI, Heidelberg University Hospital, Heidelberg, Germany.
Medical Faculty, Heidelberg University, Heidelberg, Germany.
Chair Molecular Metabolic Control, Technical University of Munich, Munich, Germany.

Cancer cachexia (CCx) is a multifactorial wasting disorder characterized by involuntary loss of body weight that affects many cancer patients and implies a poor prognosis, reducing both tolerance to and efficiency of anticancer therapies. Actual challenges in management of CCx remain in the identification of tumour-derived and host-derived mediators involved in systemic inflammation and tissue wasting and in the discovery of biomarkers that would allow for an earlier and personalized care of cancer patients. The aim of this study was to identify new markers of CCx across different species and tumour entities.

中文翻译：

循环 PLA2G7 水平与癌症恶病质的关联以及 darapladib 作为治疗的评估

癌症恶病质 (CCx) 是一种多因素消耗性疾病，其特征是体重不自主下降，影响许多癌症患者并意味着预后不良，从而降低对抗癌治疗的耐受性和效率。CCx 管理中的实际挑战仍然在于识别与全身炎症和组织消耗有关的肿瘤来源和宿主来源的介质，以及发现可以对癌症患者进行早期和个性化护理的生物标志物。本研究的目的是在不同物种和肿瘤实体中鉴定 CCx 的新标志物。

更新日期：2021-10-15

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文